Bone density; Child; Humans; Growth disorders; Growth hormone; Recombinant proteins; Syndrome; Time factors
Abstract :
[en] Objective: With the availability of recombinant insulin-like growth factor-I (recIGF-I), it was possible to study whether this peptide could promote growth without noticeable side-effects in patients with growth hormone insensitivity syndrome (Laron syndrome). We report data obtained before and during 17 months treatment using recIGF-I, 40 μg/kg s.c. twice a day, in two Lebanese siblings. Patients: The boy and the girl showed very short stature (-6.8 and -6.1 SDS), high GH (79 and 147 IU/l), low plasma IGF-I (0.12 and 0.18 U/ml) and undetectable GH binding protein. Height velocities were 4.3 and 3.8 cm/year before treatment which started at 8.4 and 6.8 years of age, respectively. Results: After 1-8 weeks of therapy, biological evidence of IGF-I effect was obtained from reduction in serum GH and increase in procollagen-I. During the first 6 months of treatment, height velocity increased to 7.8 and 8.4 cm/year without any clinical evidence of side-effects. Between 6 and 12 months, growth response decreased to 6.6 and 6.3 cm/year. Between 12 and 17 months, growth rate returned to pretreatment values. Changes in bone mineral density paralleled growth response and bone maturation ed by 1.5 and 2.0 years during the first 12 months of treatment. Daily assessment of blood sugar showed asymptomatic low values (< 2.8 mM/l) in 11/730 and 22/730 measurements in the boy and the girl, respectively. Conclusions: Treatment of two patients with growth hormone insensitivity syndrome using 40 μg/kg of IGF-I twice a day resulted in increased linear bone growth and bone mineralization as well as increased bone maturation without remarkable adverse events. After 1 year of therapy, growth response could no longer be observed in these two patients.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Heinrichs, C.
Vis, H. L.
Bergman, P.
Wilton, P.
Bourguignon, Jean-Pierre ; Université de Liège - ULiège > Département des sciences cliniques > Pédiatrie
Language :
English
Title :
Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome
Adashi, E.Y., Resnick, C.E., D'Ercole, A.J., Svoboda, M.E. & Van Wyk, J.J. (1985) Insulin‐like growth factors as intraovarian regulators of granulosa cell growth and function. Endocrine Reviews, 6, 400–420.
Baumann, G., Shaw, M.A. & Winter, R.J. (1987) Absence of the plasma growth hormone‐binding protein in Laron‐type dwarfism. Journal of Clinical Endocrinology and Metabolism, 65, 814–816.
Baumann, G., Stolar, M.W., Amburn, K., Barsano, C.P. & Devries, B.C. (1986) A specific growth hormone‐binding protein in human plasma: initial characterization. Journal of Clinical Endocrinology and Metabolism, 62, 134–141.
Chatelain, P.G., Sanchez, P. & Saez, J.M. (1991) Growth hormone and insulin‐like growth factor I treatment increase testicular luteinizing hormone receptors and steroidogenic responsiveness of growth hormone deficient dwarf mice. Endocrinology, 128, 1857–1862.
Dahms, W.T., Owens, R.P., Kalhan, S.C., Kerr, D.S. & Danish, R.K. (1989) Urea synthesis, nitrogen balance, and glucose turnover in growth‐hormone‐deficient children before and after growth hormone administration. Metabolism, 38, 197–203.
Daughaday, W.H. & Trivedi, B. (1987) Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism). Proceedings of the National Academy of Sciences, USA, 20, 8–11.
Eshet, R., Laron, Z., Pertzelan, A., Arnon, R. & Dintzmann, M. (1984) Defect of human growth hormone receptors in the liver of two patients with Laron‐type dwarfism. Israel Journal of Medical Science, 20, 8–11.
Laron, Z., Anin, S., Klipper‐Aurbach, Y. & Klinger, B. (1992) Effects of insulin‐like growth factor on linear growth, head circumference, and body fat in patients with Laron‐type dwarfism. Lancet, 339, 1258–1261.
Laron, Z., Klinger, B., Erster, B. & Anin, S. (1988) Effect of acute administration of insulin‐like growth factor I in patients with Laron‐type dwarfism. Lancet, ii, 1170–1173.
Laron, Z., Klinger, B., Jensen, L.T. & Erster, B. (1991) Biochemical and hormonal changes induced by one week of administration of rIGF‐I to patients with Laron type dwarfism. Clinical Endocrinology, 35, 145–150.
Laron, Z., Pertzelan, A. & Mannheimer, S. (1966) Genetic pituitary dwarfism with high serum concentration of growth hormone. A new inborn error of metabolism Israel Journal of Medical Science, 2, 152–155.
Pacifici, R., Rupich, R., Vered, I., Fischer, K.C., Griffin, M., Susman, N. & Avioli, L.V. (1988) Dual energy radiography: a preliminary comparative study. Calcified Tissue International, 43, 189–191.
Rolland‐Cachera, M.F., Sempé, M., Guilloud‐Bataille, M., Patois, E., Pequignot‐Guggenbuhl, F. & Fautrad, V. (1982) Adiposity indices in children. American Journal of Clinical Nutrition, 36, 178–184.
Tanner, J.M., Whitehouse, R.H. & Cameron, N. et al. (1983) Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method). Second edition. Academic Press, New York.
Walker, J.L., Ginalska‐Malinowska, M., Romer, T.E., Pucilowska, J.B. & Underwood, L.E. (1991) Effects of the infusion of insulinlike growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). New England Journal of Medicine, 324, 1483–1488.
Walker, J.L., Van Wyk, J.J. & Underwood, L.E. (1992) Stimulation of statural growth by recombinant insulin‐like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). Journal of Pediatrics, 121, 641–646.
Wilton, P. (1992) Treatment with recombinant human insulin‐like growth factor I of children with growth hormone receptor deficiency (Laron syndrome). Acta Paediatrica, 383 (Suppl.), 137–141.